Glancy Prongay & Murray and the law offices of Frank R. Cruz filed a shareholder derivative complaint Monday in Pennsylvania Eastern District Court. The suit, which alleges that misleading financial statements were made to government regulators, takes aim at the board of directors of clinical stage biopharmaceutical company Ocugen Inc., which focuses on developing gene therapies to cure blindness and a COVID-19 vaccine. Counsel have not yet appeared for the defendants. The case is 2:21-cv-03876, Musso v. Musunuri et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector. Read the complaint here: